Introduction {#s1}
============

Major depressive disorder (MDD) and other forms of clinical depression are characterized by persistent low mood with associated changes in behavior, cognition, sleep and appetite, impaired social and occupational functioning, increased risk of self-harm or suicide, and increased mortality due to co-occurring general medical disorders. Based on [@CIT0124], there is an approximately 10% lifetime international prevalence of depression, with perhaps 350 million persons currently suffering from this leading worldwide illness burden. In 2000, adult depression cost the UK approximately £9 billion, with an estimated 110 million working days lost ([@CIT0114]). In the USA in the same year, depression accounted for costs totalling over \$80 billion for treatment and disability ([@CIT0035]). These considerations indicate that depression has a major, international, clinical, public health, and economic impact.

Currently, pharmacological and non-pharmacological treatments are relatively well established as having at least moderate efficacy for the short-term treatment of acute major depression ([@CIT0115]; [@CIT0003]; [@CIT0007]). Effective antidepressants include selective serotonin (SSRIs) and serotonin-norepinephrine re-uptake inhibitors (SNRIs), a growing number of other types of modern antidepressants (such as bupropion and mirtazapine), older tricyclic (TCA) and monoamine oxidase inhibitor (MAOI) antidepressants, electroconvulsive therapy (ECT; [@CIT0003]; [@CIT0007]), and a variety of psychotherapies, including prevalent cognitive-behavioral therapy ([@CIT0013]; [@CIT0104]).

Despite generally effective short-term treatments for acute episodes of major depression, many patients experience relapses (early return of symptoms within the expected duration of a current episode, of perhaps 3--12 months) or later recurrences (new episodes) following initial short-term improvement or remission ([@CIT0036]; [@CIT0030]; [@CIT0031]). Recurrence rates are over 85% within a decade of an index depressive episode, and average approximately 50% or more within six months of apparent clinical remission if the initially-effective treatment was not continued ([@CIT0003]). The median time to a new episode with antidepressant treatment continued has averaged approximately 40 months, compared to just over 1 year if treatment was discontinued ([@CIT0003]; [@CIT0097]). With such high rates of relapse and recurrence, it has become usual practice to continue initially-effective antidepressant treatments for at least 6--12 months following apparent clinical remission of acute depression, and often longer for patients who have experienced multiple recurrences ([@CIT0003]). Nevertheless, clinically-treated patients diagnosed with MDD in long-term observational studies are depressed 40--50% of the time at follow-up ([@CIT0031]).

Earlier reviews and meta-analyses and recent treatment guidelines for long-term treatment of MDD are generally supportive of treatments continued for several months as well as more than a year, particularly pharmacotherapies ([@CIT0034]; [@CIT0069]; [@CIT0089]; [@CIT0122]; [@CIT0040]; [@CIT0007]). In view of the clinical importance of evaluating the effectiveness of continued and long-term treatment to prevent relapses and recurrences of major depression, we updated and extended previous reviews of portions of available research findings by separately examining reports of research trials involving continuation (up to 12 months following initial treatment) or long-term treatments (more than a year), as well as long-term trials of psychotherapy, all aimed at prophylaxis or prevention of relapses and recurrences of depressive illness.

Methods {#s2}
=======

Search Strategy and Selection Criteria {#s3}
--------------------------------------

References for this review were identified through searches of the National Centre of Biotechnology Information, Pubmed/Medline, Scieverse, SciDirect, and Web-of-Science databases for reports published up to February 2015. Search terms were combinations of: adult; depress; major depress; long-term; prevent; relapse; recurrence; treatment; and generic names of specific antidepressant drugs. We reviewed reports identified in these searches and in relevant references cited in identified articles.

Inclusion/Exclusion Criteria {#s4}
----------------------------

A report was selected for inclusion if: (a) it examined relapse or recurrence of major depressive disorder in adults treated with pharmacological or non-pharmacological means; and (b) it was reported in English. Reports were excluded if they concerned: (a) bipolar depression; (b) seasonal depression; (c) juvenile depression; or (d) studied only adverse events or costs.

Data Extraction {#s5}
---------------

For each included report two investigators (Drs J Sim and Lau) independently extracted relevant data, including numbers and types of subjects, study design, treatments and controls, definitions of relapse and recurrence, nominal duration of treatment, dropout rates, and outcomes as rates of relapse or recurrence. Discrepancies were resolved by discussions and consensus amongst all team members.

Data Analysis {#s6}
-------------

Extracted data were organized in digitalized spreadsheets and then summarized in tables to guide assessments. We subjected comparisons of active and control treatments to random-effects meta-analysis to obtain relative response rates (RRs) for active treatments versus controls, with their 95% confidence intervals (CIs), as well as rate differences (RDs) and their reciprocals (1/RD = number-needed-to-treat \[NNT\]), both with CIs. Averaged data are presented as means ± standard deviation (SD) or with CI. Statistical analyses employed data spreadsheets based on *Statview.5* (SAS Institute) and *Stata.13* statistical software (StataCorp.).

Results {#s7}
=======

Retrieved Studies {#s8}
-----------------

Initially, we identified 803 candidate reports, of which four represented second reports of the same study; of the 799 remaining citations, we excluded 653 as not meeting study inclusion/exclusion criteria. The remaining 146 full reports were reviewed in detail; 49 were excluded for having participants with diagnoses other than MDD, involving participants below 18 years old, or not specifying subject numbers and trial durations. This process left 97 reports for inclusion; two provided data for more than one of the following categories ([@CIT0048]; [@CIT0013]). Reported study categories were: (a) intermediate-term (1--12 months) continuation trials of antidepressant treatment (n = 45); (b) long-term (≥12 months) trials of antidepressants (n = 35); and (c) long-term trials of psychosocial interventions (n = 17; [supplementary Tables S1--S3](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv076/-/DC1)). The screening and selection process is summarized in a Prisma flow chart ([Figure 1](#F1){ref-type="fig"}).

![Flow chart of study selection process: 803 reports screened, 146 reviewed in detail, and 97 included for analysis, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations (<http://www.prisma-statement.org/statement.htm>).](ijnppy_pyv076_f0001){#F1}

Continuation Trials of Antidepressants {#s9}
--------------------------------------

We identified 45 reports involving 72 placebo-controlled trials of different antidepressants, representing a total of 14 450 participants ([Tables 1](#T1){ref-type="table"} and [S1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv076/-/DC1)). Of these, four studies included two active treatments or two doses of one antidepressant versus a single placebo-treated group ([@CIT0070]; [@CIT0083]; [@CIT0101]; [@CIT0100]). Observed relapse rates in each randomized treatment arm of the trials, and other salient characteristics of each study, are shown in [Table S1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv076/-/DC1).

###### 

Meta-Analyses of Placebo-Controlled Trials of Continuation Treatments (≤12 months) for Major Depression

  Trial                             Treatment                Subjects   RR (95% CI)         NNT (95% CI)         Weight (%)
  --------------------------------- ------------------------ ---------- ------------------- -------------------- ------------
  Mindham et al., 1973              Amitriptyline            61         2.83 (1.46--5.49)   2.3 (1.5--4.9)       1.15
  Mindham et al., 1973              Imipramine               31         1.07 (0.25--4.49)   80 (3.4 to \>100)    0.36
  Klerman et al., 1974              Amitriptyline            50         2.33 (0.68--8.01)   6.2 (2.6 to \>100)   0.46
  Coppen et al., 1978               Amitriptyline            32         1.56 (0.45--5.43)   8.9 (2.4 to \>100)   0.45
  Stein et al., 1980                Amitriptyline            55         2.23 (1.22--4.06)   2.6 (1.6--7.3)       1.28
  Van Praag and De Haan, 1980       Clomipramine             20         2.66 (0.98--7.22)   2.0 (1.1--8.1)       0.65
  Bialos et al., 1982               Amitriptyline            17         12.4 (0.83--184)    1.2 (0.9--2.0)       0.11
  Kane et al., 1982                 Imipramine+Lithium       14         8.00 (1.28--50.0)   1.1 (0.8--1.8)       0.23
  Kane et al., 1982                 Lithium                  13         3.50 (1.08--11.3)   1.4 (0.9--2.9)       0.50
  Kane et al., 1982                 Imipramine               12         1.50 (0.85--2.64)   3.0 (1.4 to \>100)   1.37
  Davidson and Raft, 1984           Phenelzine               15         6.12 (0.98--38.3)   1.4 (0.9--2.6)       0.23
  Lendresse et al., 1985            Nomifensine              143        2.03 (1.17--3.52)   5.0 (2.9--18)        1.40
  Cook et al., 1986                 Tricyclics               15         4.90 (0.30--80.7)   3.0 (1.5 to \>100)   0.10
  Harrison et al., 1986             Phenelzine               12         5.00 (0.87--28.9)   1.2 (0.8--2.4)       0.25
  Montgomery et al., 1988           Fluoxetine               182        2.20 (1.49--3.25)   3.2 (2.2--5.6)       1.88
  Georgotas et al., 1989            Nortriptyline            36         1.21 (0.67--2.17)   8.8 (2.2 to \>100)   1.32
  Georgotas et al., 1989            Phenelzine               38         4.89 (1.30--18.4)   1.9 (1.3--3.9)       0.41
  Quitkin et al., 1989              Imipramine               54         1.69 (1.10--2.60)   3.0 (1.7--11)        1.75
  Quitkin et al., 1989              Phenelzine               53         1.93 (1.19--3.12)   2.6 (1.6--6.6)       1.59
  Rouillon et al., 1989             Maprotiline              1 141      1.44 (1.13--1.84)   14 (8.2--45)         2.38
  Doogan and Caillard, 1992         Sertraline               295        3.50 (2.29--5.36)   3.1 (2.3--4.5)       1.77
  Montgomery et al., 1993b          Citalopram               155        3.05 (1.53--6.09)   4.6 (2.8--14)        1.09
  Montgomery et al., 1993a          Paroxetine               135        2.68 (1.46--4.91)   3.7 (2.4--8.1)       1.27
  Mynors-Wallis et al., 1995        Amitriptyline            61         3.10 (1.43--6.73)   2.5 (1.6--5.5)       0.94
  Robert and Montgomery, 1995       Citalopram               226        1.76 (1.00--3.10)   9.5 (4.6 to \>100)   1.37
  Lauritzen et al., 1996            Paroxetine               58         6.33 (2.11--19.1)   1.8 (1.3--2.9)       0.56
  Lauritzen et al., 1996            Imipramine               58         2.11 (1.16--3.86)   2.9 (1.7--9.7)       1.28
  Cunningham, 1997                  Venlafaxine              278        1.37 (0.99--1.90)   8.9 (4.3 to \>100)   2.10
  Stewart et al., 1997              Phenelzine               28         3.76 (1.36--10.3)   1.6 (1.1--2.9)       0.64
  Stewart et al., 1997              Imipramine               32         1.13 (0.52--2.48)   18 (2.5 to \>100)    0.92
  M Fava et al., 1998               Paroxetine               73         1.00 (0.46--2.17)   \>100                0.95
  M Fava et al., 1998               Fluoxetine               74         0.72 (0.28--1.90)   \>100                0.69
  Montgomery et al., 1998           Mirtazapine              387        6.78 (3.32--13.9)   4.2 (5.9--6.8)       1.04
  Montgomery et al., 1998           Amitriptyline            386        2.45 (1.56--3.86)   6.0 (4.1--11)        1.68
  Feiger et al., 1999               Nefazodone               467        1.96 (1.39--2.75)   6.3 (4.2--12)        2.05
  Silverstone and Ravindran, 1999   Fluoxetine               237        1.53 (1.05--2.23)   7.3 (3.9--52)        1.93
  Silverstone and Ravindran, 1999   Venlafaxine-XR           240        1.39 (0.97--1.98)   9.0 (4.3 to \>100)   2.00
  Versiani et al., 1999             Reboxetine               283        2.57 (1.79--3.69)   3.1 (2.4--4.7)       1.98
  Bauer et al., 2000                Lithium                  28         1.50 (0.94--2.40)   2.0 (1.3--4.3)       0.11
  Schmidt et al., 2000              Fluoxetine 90 mg         312        1.36 (1.05--1.76)   7.6 (4.1--51)        2.34
  Schmidt et al., 2000              Fluoxetine 20 mg         311        1.93 (1.43--2.60)   4.2 (2.9--7.6)       2.19
  Sackeim et al., 2001              Nortriptyline+Lithium    48         2.15 (1.25--3.68)   2.2 (1.4--4.9)       1.44
  Sackeim et al., 2001              Nortriptyline            50         1.40 (0.97--2.01)   4.2 (2.1 to \>100)   1.98
  Thase et al., 2001                Mirtazapine              156        2.41 (1.45--4.00)   3.6 (2.4--7.3)       1.52
  Bschor et al., 2002               Lithium                  22         0.70 (0.17--2.81)   \>100                0.38
  Golden et al., 2002               Paroxetine-CR            423        0.62 (0.32--1.21)   \>100                1.14
  Golden et al., 2002               Paroxetine-IR            428        0.38 (0.21--0.70)   \>100                1.27
  Weihs et al., 2002                Bupropion                828        1.41 (1.20--1.64)   6.7 (4.6--12)        2.64
  Fava et al., 2005                 Hypericum                88         1.28 (0.81--2.03)   9.0 (3.1 to \>100)   1.66
  Fava et al., 2005                 Fluoxetine               90         1.05 (0.69--1.58)   45 (4.4 to \>100)    1.81
  Amsterdam and Bodkin 2006         Selegiline-transdermal   312        1.95 (1.34--2.83)   5.2 (3.4--11)        1.94
  Perahia et al., 2006              Duloxetine               269        1.63 (1.04--2.58)   9.1 (4.8--91)        1.67
  van den Broek et al., 2006        Imipramine               26         4.40 (1.22--15.8)   1.6 (1.1--3.2)       0.43
  Goodwin et al., 2009              Agomelatine              492        1.96 (1.48--2.59)   5.1 (3.5--8.9)       2.26
  Rickels et al., 2010              Desvenlafaxine           374        1.77 (1.30--2.40)   5.4 (3.6--11)        2.17
  Yildiz et al., 2010               Antidepressants          46         2.14 (1.08--4.26)   2.9 (1.6--13)        1.10
  Rosenthal et al., 2013            Desvenlafaxine           548        2.08 (1.46--2.96)   6.8 (4.7--13)        2.01
  Borges et al., 2014               Not stated               224        1.96 (1.29--2.97)   5.0 (3.1--14)        1.80
  Borges et al., 2014               Not stated               258        1.78 (1.24--2.56)   5.4 (3.3--14)        1.97
  Borges et al., 2014               Not stated               226        2.14 (1.60--2.88)   2.9 (2.1--4.7)       2.21
  Borges et al., 2014               Not stated               147        2.14 (1.08--4.24)   6.6 (3.3 to \>100)   1.10
  Borges et al., 2014               Not stated               298        4.87 (2.85--8.30)   3.3 (2.4--5.0)       1.45
  Borges et al., 2014               Not stated               125        2.72 (1.24--5.98)   5.1 (3.0--17)        0.92
  Borges et al., 2014               Not stated               213        1.72 (0.97--3.05)   9.9 (4.8 to \>100)   1.34
  Borges et al., 2014               Not stated               292        3.20 (1.86--5.50)   4.7 (3.3--8.1)       1.43
  Borges et al., 2014               Not stated               156        1.49 (1.07--2.08)   5.2 (2.9--26)        2.08
  Borges et al., 2014               Not stated               417        7.15 (2.56--20.0)   8.4 (5.9--15)        0.62
  Borges et al., 2014               Not stated               312        1.93 (1.40--2.66)   4.3 (3.0--7.9)       2.12
  Borges et al., 2014               Not stated               273        1.69 (1.22--2.34)   5.4 (3.3--15)        2.10
  Borges et al., 2014               Not stated               269        2.22 (1.50--3.29)   4.1 (2.9--7.5)       1.87
  Borges et al., 2014               Not stated               374        1.42 (1.11--1.82)   7.0 (4.1--23)        2.36
  Borges et al., 2014               Not stated               548        1.93 (1.40 -2.66)   6.7 (4.5--13)        2.11
  *Pooled* (72 comparisons)         ------                   14 450     1.90 (1.73--2.08)   4.4 (3.8--5.2)       100

By random-effects meta-analysis, pooled relative risk (RR 1.90; *z* = 13.3) and pooled number needed to treat (NNT 4.4; *z* = 12.7) were both highly significant, even in a sensitivity meta-analysis, omitting eight trials with RR ≥ 5.0 (RR 1.81, CI 1.66--1.97; *z* = 12.7; all *p*\<0.0001); 23/72 trials (31.9%) individually yielded non-significant drug-placebo differences.

In these continuation trials, drug treatments continued for an average of 8.35 (CI 7.55--9.15) months. Risk of relapse within several months of initial remission averaged 23.3% with antidepressant continued versus 49.4% after discontinuing treatment, a 2.1-fold difference ([Table S1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv076/-/DC1)). The meta-analytically computed, pooled relative, placebo/drug relapse rate was 1.90 (CI: 1.73--2.08), a highly significant decrease (*z*-score = 13.3, *p* \< 0.0001; [Table 1](#T1){ref-type="table"}). Even when eight trials with unusually high drug-placebo differences (\>5-fold; [Table S1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv076/-/DC1)) were removed in a sensitivity re-analysis, the difference between continued antidepressant treatment and placebo remained highly significant. The overall computed number-needed-to-treat (NNT), or number of cases to be treated to obtain one responding better with drug than with placebo was low (4.4, CI 3.8--5.2).

Long-Term Antidepressant Treatment {#s10}
----------------------------------

We identified a total of 35 reports involving treatment with antidepressants continued for more than one year (2.27, CI 1.88--2.62 years) following an index episode of acute major depression, with a total of 7253 participants in 37 drug-control comparisons ([Tables 2](#T2){ref-type="table"} and [S2](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv076/-/DC1)). All but one of these trials compared an antidepressant to a placebo; the single exception involved a small, 5.4-year comparison of antidepressant treatment alone versus with continued ECT, in which the addition of ECT yielded a significantly lower recurrence rate (27.6% vs. 82.8%; [@CIT0033]).

###### 

Meta-analysis of long-term (\>12 months) trials of antidepressants versus placebo in major depressive disorder

  Trial                       Treatment               Subjects   RR \[95%CI\]          NNT \[95%CI\]          \% Weight          
  --------------------------- ----------------------- ---------- --------------------- ---------------------- ------------------ -----
  Bjork 1983                  Zimelidine              38         2.67 \[1.34--5.32\]   1.9 \[1.3--3.8\]       1.83               
  Glen et al. 1984            Amitriptyline           67         1.41 \[1.04--1.84\]   3.9 \[2.0--59\]        3.67               
  Glen et al. 1984            Lithium                 78         1.37 \[1.03--1.92\]   4.1 \[2.1--139\]       3.78               
  Prien et al. 1984           Amitriptyline±Lithium   150        1.91 \[1.32--2.78\]   3.5 \[2.3--7.4\]       3.28               
  Frank et al. 1990           Imipramine+IPT          51         2.72 \[1.28--5.78\]   2.4 \[1.5--6.0\]       1.64               
  Robinson et al. 1991        Phenelzine              47         2.80 \[1.54--5.09\]   1.9 \[1.3--3.7\]       2.17               
  Kupfer et al. 1992          Imipramine+IPT          20         7.33 \[1.07--50.3\]   1.7 \[1.1--4.5\]       0.35               
  Maj et al. 1992             Tricyclics±Lithium      72         1.22 \[0.97--1.52\]   6.3 \[2.9 to \>100\]   4.17               
  OADIG 1993                  Dothiepin               69         1.83 \[1.01--3.32\]   4.0 \[2.1--37\]        2.19               
  Kishimoto et al. 1994       Mianserin               22         2.25 \[1.08--4.67\]   1.8 \[1.1--4.3\]       1.71               
  Entsuah et al. 1996         Venlafaxine             448        1.69 \[1.23--2.32\]   7.2 \[4.6--18\]        3.61               
  Kocsis et al. 1996          Desipramine             129        4.79 \[2.29--10.0\]   2.4 \[1.8--3.8\]       1.68               
  Keller et al. 1998          Sertraline              161        3.48 \[1.37--8.88\]   6.2 \[3.8--18\]        1.20               
  Terra and Montgomery 1998   Fluvoxamine             436        2.75 \[1.86--4.06\]   4.4 \[3.3--6.8\]       3.20               
  Reynolds et al. 1999        Nortriptyline           107        2.42 \[1.60--3.68\]   2.2 \[1.6--3.5\]       3.04               
  Alexopoulos et al. 2000     Nortriptyline           43         2.88 \[1.09--7.64\]   2.9 \[1.6--13\]        1.13               
  Gagne et al. 2000           ECT+Antidepressants     58         3.00 \[1.63--5.54\]   1.8 \[1.3--3.0\]       2.11               
  Rouillon et al. 2000        Milnacipran             214        1.45 \[0.83--2.50\]   14 \[5.6 to \>100\]    2.38               
  Gilaberte et al. 2001       Fluoxetine              253        2.02 \[1.34--3.04\]   5.0 \[3.2--11\]        3.07               
  Hochstrasser et al. 2001    Citalopram              264        3.45 \[2.47--4.82\]   1.9 \[1.6--2.3\]       3.51               
  Klysner et al. 2002         Citalopram              121        2.12 \[1.41--3.20\]   2.8 \[1.9--5.3\]       3.08               
  Gelenberg et al. 2003       Nefazodone              160        1.57 \[1.05--2.37\]   5.8 \[3.1--40\]        3.09               
  Wilson et al. 2003          Sertraline              113        1.18 \[0.80--1.73\]   13 \[3.8 to \>100\]    3.24               
  Lepine et al. 2004          Sertraline              288        1.97 \[1.29--3.00\]   6.1 \[3.7--18\]        3.02               
  Montgomery et al. 2004      Venlafaxine             225        2.51 \[1.70--3.70\]   3.0 \[2.2--4.7\]       3.20               
  Hollon et al. 2005          Antidepressants         69         1.64 \[1.10--2.44\]   3.3 \[1.9--12\]        3.14               
  Keller et al. 2005          Gepirone                420        1.52 \[1.12--2.07\]   8.4 \[4.9--30\]        3.66               
  Kornstein et al. 2006       *S*-Citalopram          139        2.38 \[1.57--3.59\]   2.6 \[1.9--4.5\]       3.06               
  Reynolds et al. 2006        Paroxetine+CM           53         1.92 \[1.11--3.31\]   3.0 \[1.8--11\]        2.40               
  Reynolds et al. 2006        Paroxetine+PT           63         1.50 \[0.82--2.72\]   5.4 \[1.8 to \>100\]   2.18               
  Keller et al. 2007a         Venlafaxine             131        5.89 \[2.43--14.3\]   2.7 \[2.2--4.3\]       1.31               
  Kocsis et al. 2007          Venlafaxine-ER          336        1.82 \[1.31--2.52\]   5.5 \[3.5--11\]        3.56               
  Kasper et al. 2008          Hypericum               426        1.42 \[0.98--2.06\]   13 \[6.3 to \>100\]    3.29               
  Kelin et al. 2010           Duloxetine              514        2.53 \[1.75--3.67\]   5.3 \[3.8--8.3\]       3.30               
  Liebowitz et al. 2010       Quetiapine-ER           771        2.42 \[1.83--3.20\]   5.0 \[3.8--7.0\]       3.84               
  Segal et al. 2010           Antidepressants         58         2.60 \[1.32--5.11\]   2.3 \[1.5--5.2\]       1.88               
  Boulenger et al. 2012       Vortioxetine            639        1.97 \[1.29--3.01\]   7.8 \[4.9--20\]        3.00               
  *Pooled* (37 comparisons)   ------                  7253       2.03 \[1.80--2.28\]                          3.8 \[3.3--4.6\]   100

Based on 35 placebo-controlled trials (except for Gagne et al., with antidepressants-only as controls), with 37 drug/control comparisons, lasting \>12 (14--60) months shown in eTable S2, with random-effects meta-analytic modeling. Total N includes 9 controls used twice (for Glen et al. 1984). The pooled RR (recurrence rate with placebo/drug) indicates highly significant overall superiority versus placebo (*z*=11.7, *p*\<0.0001); 5/37 trials (13.5%) individually yielded nonsignificant drug-control differences. *Abbreviations*: *CM*, clinical management; *ECT*, electroconvulsive treatment; *ER*, extended release; *IPT*, interpersonal psychotherapy; NNT = number-needed-to-treat to yield a selective response to drug \> placebo; *PT*, psychotherapy.

Based on random-effects meta-analysis ([Table 2](#T2){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}), all but five of the 37 (86.4%) drug-placebo comparisons trials yielded statistically superior benefits of active agents over placebo treatment in reducing recurrence risk. All but five trials ([@CIT0076]; [@CIT0099]; [@CIT0123]; [@CIT0093]; [@CIT0051]) yielded statistically superior benefits of active agents over placebo treatments in reducing recurrence risk. These failed trials involved antidepressants such as tricyclic antidepressants ([@CIT0076]), SSRIs ([@CIT0123]; [@CIT0093]), the anxiolytic SNRI milnacipran ([@CIT0099]), and a preparation of the plant *Hypericum perforatum* (St. John's Wort; [@CIT0051]). Overall, the long-term, controlled trials yielded significantly greater protection from recurrences with antidepressants versus placebo treatments (RR 2.03, CI 1.80--2.28; *z* = 11.7, *p* \< 0.0001), with a low number-needed-to-treat (NNT 3.8, CI 3.3--4.6). That is, recurrence risk was reduced by 2.03-fold or 50.7% with long-term antidepressant treatment ([Figure 2](#F2){ref-type="fig"}).

![Findings from random-effects meta-analysis of 37 controlled, long-term trials (\>12 months) of antidepressants vs. placebos in major depression. The pooled ratio (RR) of recurrence risk with placebo vs. antidepressants, of 2.03 \[CI: 1.80-2.28\]) is highly significant (*z*-score = 11.7, *p* \< 0.0001).](ijnppy_pyv076_f0002){#F2}

Psychosocial Treatments {#s11}
-----------------------

A variety of psychosocial methods were tested in 17 trials with 22 tested treatments, averaging 1.98 (CI 1.49--2.46) years and involving 1 969 participants ([Tables 3](#T3){ref-type="table"} and S3). Treatment techniques included various forms of cognitive or cognitive-behavioral psychotherapy (CT or CBT), sometimes with a mindfulness orientation (MCT), and patient- or family-based psychoeducation, with or without antidepressant treatment. Controls typically involved treatment as usual (often involving continued use of antidepressants, or placebo controls for comparisons in which antidepressants were involved). This heterogeneous group of studies yielded varied findings, as might be expected. Statistically nonsignificant results were reported in at least one component of 11 of the trials (50.0%; [Tables 3](#T3){ref-type="table"} and [S3](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv076/-/DC1)). A notable finding in four of the trials (all involving CT or MCT) is that presumably more severely ill patients, with at least three or five pre-trial recurrences of depressive episodes, showed greater responses to treatment than subjects with fewer recurrences ([@CIT0075]; [@CIT0010], [@CIT0012]; [@CIT0110]).

###### 

Meta-Analysis of Controlled, Long-Term Trials of Psychosocial Treatments for Major Depression

  ---------------------------------------------------------------------------------------------------------------------
  Trials                      Subjects   Treatment     Controls   RR (95% CI)         NNT (95% CI)         Weight (%)
  --------------------------- ---------- ------------- ---------- ------------------- -------------------- ------------
  Shea et al., 1992           37         CBT           Pbo        0.92 (0.37--2.26)   \>100                3.06

  Shea et al., 1992           36         IPT           Pbo        1.00 (0.39--2.55)   \>100                2.93

  GA Fava et al., 1998        40         CBT+AD        AD         3.20 (1.45--7.05)   1.8 (1.2--3.4)       3.58

  Gortner et al., 1998        151        CBT           CM         0.73 (0.50--1.08)   \>100                6.06

  Teasdale et al., 2000 ^a^   73         MCT (high)    TAU        1.64 (1.04--2.59)   3.8 (2.1--25)        5.63

  Teasdale et al., 2000 ^b^   72         MCT (low)     TAU        0.55 (0.31--0.98)   \>100                4.82

  Jarrett et al., 2001        156        CBT           TAU        3.00 (1.44--6.26)   4.9 (3.1--12)        3.86

  Katon et al., 2001          386        PsychoEd      TAU        0.98 (0.75--1.29)   \>100                6.85

  Klein et al., 2004          82         CBT           TAU        3.25 (1.15--9.14)   4.6 (2.6--20)        2.58

  Ma & Teasdale, 2004 ^a^     38         MCT (high)    TAU        0.98 (0.68--1.26)   1.4 (1.1--1.9)       0.98

  Ma & Teasdale, 2004 ^b^     38         MCT (low)     TAU        0.40 (0.15--1.06)   \>100                2.81

  Bockting et al., 2005 ^a^   71         CT (high)     TAU        1.54 (1.02--2.32)   4.1 (2.1--41)        5.92

  Bockting et al., 2005 ^b^   101        CT (low)      TAU        0.93 (0.68--1.26)   \>100                6.66

  Hollon et al., 2005         70         CT            Pbo        2.45 (1.46--4.13)   2.2 (1.5--4.0)       5.16

  Dobson et al., 2008         79         CT            AD         2.19 (1.08--4.42)   3.6 (2.1--14)        4.03

  Dobson et al., 2008         76         BA            AD         2.00 (1.00--4.02)   3.8 (2.1--23)        4.09

  Kuyken et al., 2008         123        MCT           AD         1.26 (0.90--1.75)   8.2 (3.4 to \>100)   6.46

  Bockting et al., 2009 ^a^   86         CT (high)     TAU        1.28 (1.06--1.53)   11 (2.8--16)         7.33

  Bockting et al., 2009 ^b^   86         CT (low)      TAU        0.97 (0.79--1.20)   \>100                7.22

  Bondolfi et al., 2010       60         MCT           TAU        1.19 (0.56--2.50)   18 (3.4 to \>100)    3.81

  Segal et al., 2010          54         MCT           Pbo        2.45 (1.30--4.60)   2.4 (1.5--5.6)       4.46

  Shimazu et al., 2011        54         FamPsychoEd   TAU        6.00 (1.52--23.7)   2.4 (1.6--4.8)       1.71

  *Pooled*\                   1 969      ------        ------     1.39 (1.13--1.70)   6.0 (3.8--14)        100
  (22 comparisons)                                                                                         
  ---------------------------------------------------------------------------------------------------------------------

Based on random-effects meta-analysis of data in Supplementary Table S3, omitting drug arms and trials lacking separate control arms. The pooled RR of 1.39 is statistically significant (*z* = 3.15, *p* = 0.002), although 11 of 22 (50.0%) comparisons involved non-significant differences between experimental psychosocial treatments and controls.

In four studies, differences were found among subgroups with relatively ^a^high (≥3 or ≥5) vs. ^b^lower numbers of previous depressive recurrences. With high recurrences, pooled RR = 1.63 (1.04--2.57; *z* = 2.14, *p* = 0.03); with low recurrences, RR = 0.80 (0.58--1.09; *z* = 1.41, *p* = 0.16).

AD, antidepressants; BA, behavioral activation therapy; CBT, cognitive behavioral therapy; CI, confidence interval; CT, cognitive psychotherapy; FamPsychoEd, family psychoeducation; IPT, interpersonal psychotherapy; MCT, mindfulness-oriented cognitive therapy; Pbo, placebo; PsychoEd, psychoeducation; RR, recurrence rate; TAU, treatment as usual.

Meta-Regression Analyses {#s12}
------------------------

Following random-effects meta-analyses, we used meta-regression modeling to test for associations of outcomes of trials reported in [Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"} and S1--S3 with available potential covariates. These factors included: (a) year study was reported; (b) trial size (total number of subjects); (c) mean age of subjects; (d) proportion of women participants; (e) estimated counts of previous depressive episodes; (f) initial weeks of treatment prior to randomization; (g) month duration of continuation or long-term trials; (h) type of antidepressant (older agents \[TCAs, the atypical agents dothiepin and mianserin, or MAO inhibitors\] vs. newer agents \[SSRIs or SNRIs, mirtazapine, or bupropion\]).

Regarding meta-analysis of intermediate-term continuation trials ([Tables 1](#T1){ref-type="table"} and S1), meta-regression found only one of the eight stated factors to be significantly associated with efficacy of active treatments over placebo. It was the duration (weeks) of initial treatment and clinical stabilization of subjects presenting in acute depressive episodes prior to randomization into a continuation phase of each trial. That is, longer initial treatment was associated significantly with a larger drug-placebo contrast (greater effect size, whether based on placebo/drug RR or the difference in relapse rates between placebo and antidepressant, RD) during continuation treatment (β slope function = +0.048; CI 0.024--0.073; *z* = 3.90, *p* \< 0.001).

Meta-regression analysis for long-term medication maintenance trials ([Tables 2](#T2){ref-type="table"} and S2) also found only one factor to be significantly associated with outcomes in meta-analysis. That is, longer duration (months) had a positive effect on drug-placebo contrasts (β slope function = +0.104; CI 0.044--0.163; *z* = 3.44, *p* \< 0.001). In addition, with linear regression modeling, recurrence rates with both drug and placebo increased with longer exposure time, as expected, although recurrence risk with placebo grew much more than with drug (*r* = +0.57 vs. +0.30, respectively). It follows that both their RR and RD grew larger, with longer treatment indicating greater effect size (*r* = +0.47 and +0.41, respectively, both *t*-scores ≥2.56, with *p* ≤ 0.01), consistent with the meta-regression analysis.

Meta-regression modeling for findings in long-term psychotherapy trials ([Tables 3](#T3){ref-type="table"} and S3) indicated that none of the factors listed above was significantly associated with larger effect-sizes in random-effect meta-analysis. However, when trials involving high (≥3 or ≥5) versus low counts of previous depressive episodes were pooled for random-effects meta-analysis, there was a much greater effect of psychosocial interventions after higher recurrence counts.

Effect of Type of Treatment {#s13}
---------------------------

We also summarized meta-analytic results for comparisons of specific types of antidepressants versus placebo controls in long-term trials summarized in [Table 2](#T2){ref-type="table"}. Only TCAs (n = 10) and the pool of SSRIs (n = 11) and SNRIs (n = 7) provided at least 10 trials for meta-analysis, and all yielded similar RR values (2.09, 2.10, and 2.17, respectively). Overall, computed RR values (relative recurrence with placebo/antidepressant: greater, better) ranked: ECT (RR = 3.00) \> MAO inhibitor (2.80) \> SSRIs (2.17) ≥ SNRIs (2.10) ≥ TCAs (2.09) \> various standard antidepressants (1.91) \> atypical agents (gepirone, hypericum, mianserin, nefazodone, or quetiapine-ER; 1.72) \> lithium (1.39), but all active agent types were significantly superior to placebo.

Summary of Findings {#s14}
-------------------

Finally, salient characteristics of the information found regarding: (a) continuation of antidepressant treatment up to 12 months (72 trials with 14 450 subjects) after an acute depressive episode; (b) long-term maintenance treatment with antidepressants (37 trials with 7253 subjects); and (c) long-term use or addition of psychosocial treatments (22 trials with 1 969 subjects) are summarized in [Table 4](#T4){ref-type="table"}. By trial-type, meta-analytically computed values of effect-size (RR) ranked: b, long-term antidepressants (2.02) \> a, continuation of antidepressants (1.90) \> c, long-term psychosocial treatments (1.39). Similarly, computed NNT values ranked inversely in the same order (b, 3.8 \< a, 4.4 ≤ c, 6.0), as did the rate of trials finding superior outcomes with test treatment versus controls (b, 86.5% \> a, 68.1% \> c, 50.0%).

###### 

Summary of Meta-Analytic Findings from Controlled Trials for Continuation or Maintenance Treatments for Recurrent Major Depression

  Measures                                                      Drug Continuation   Drug Maintenance    Psychosocial Maintenance
  ------------------------------------------------------------- ------------------- ------------------- --------------------------
  Reports                                                       45                  35                  17
  Controlled trials                                             72                  37                  22
  Years                                                         1 973--2 014        1 983--2 012        1 992--2 011
  *Subjects*                                                                                            
   Total                                                        14 450              7253                1 969
   Per trial                                                    189 (138--239)      188 (131--245)      124 (92.1--156)
  Mean age                                                      48.3 (46.0--50.6)   47.5 (42.5--52.1)   44.6 (44.0--48.2)
  \% Women                                                      60.4 (56.4--64.4)   69.5 (37.3--71.7)   69.6 (64.7--75.5)
  Duration (mos)                                                8.35 (7.55--9.15)   26.8 (25.5--31.1)   23.7 (18.4--29.0)
  RR (95% CI)                                                   1.90 (1.73--2.08)   2.03 (1.80-2.28)    1.39 (1.13--1.70)
  *z*-score (*p*-value)                                         13.3 (\<0.0001)     11.7 (\<0.0001)     3.15 (0.002)
  NNT (95% CI)                                                  4.4 (3.8--5.2)      3.8 (3.3--4.6)      6.0 (3.8--14)
  Trials with significant superiority of test treatment (%)\*   49/72 (68.1%)       32/37 (86.5%)       11/22 (50.0%)

Recurrence rate (RR) is meta-analytically pooled risk of new depression with placebo or control treatment vs. active experimental treatment. Data are derived from [Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"} and Supplementary Tables S1--3. \*Success-rate is significantly greater for drug vs. psychosocial maintenance treatments (χ^2^ = 6.29, *p* = 0.01) and for all drug vs. psychosocial treatments (χ^2^ = 4.72, *p* = 0.03), but not between continuation and maintenance drug treatment (χ^2^ = 2.80, *p* = 0.09).

CI, confidence interval; NNT, number needed to treat to yield a selective response to drug \> placebo.

Discussion {#s15}
==========

Most pharmacotherapy trials for MDD patients found significant reductions of early relapse (up to 12 months) or of long-term recurrence rates with active drugs compared to placebo controls ([Tables 1](#T1){ref-type="table"}, [12](#T1){ref-type="table"}, S1, and S2, [Figure 2](#F2){ref-type="fig"}). Differences between specific types of treatments or specific agents were insufficiently studied except for TCA, SSRI, and SNRI antidepressants, all of which appeared to provide similar long-term benefits. Long-term trials of psychotherapy for depression were relatively fewer and have yielded variable findings ([Tables 3](#T3){ref-type="table"} and S3). Family psychoeducation appeared to be useful long-term in two studies reported from Japan ([@CIT0105]; [@CIT0106]).

Continuation and Long-Term Pharmacological Treatments {#s16}
-----------------------------------------------------

In most continuation and long-term maintenance trials, antidepressant drugs proved to be more effective than placebo controls ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Of the total of 109 such trials of efficacy in preventing relapses or recurrences of major depression, 81 (74.3%) yielded statistically significant differences favoring a variety of types of antidepressants (68.1% of continuation trials and 86.5% of maintenance trials). The most frequently studied antidepressants were SSRIs and SNRIs, which outperformed placebo controls in 11 of 20 (55.0%) continuation trials and 13 of 15 (86.7%) maintenance trials. Based on the results of meta-analysis, the relative risk of new episodes of depression with these modern drugs and TCAs was very similar, and the numbers of trials of other types of treatments was too limited to support secure conclusions about comparative efficacy. These findings appear to support the clinical value of extending antidepressant treatment for up to 12 months after initial improvement or remission of acute depression, as well as the value of long-term antidepressant treatment, at least when indications based on the demonstrated risk of recurrences, and of probable benefit, are present.

Non-Pharmacological Treatments {#s17}
------------------------------

The effects of psychosocial treatments, with or without antidepressants, yielded inconsistent and largely inconclusive findings ([Table 3](#T3){ref-type="table"}). Among these, notably, family psychoeducation continued for up to 10 months was examined in two Japanese studies and found to be clinically effective and cost-effective in reducing recurrence risks in major depressive disorder patients ([@CIT0105]; [@CIT0106]). Mindfulness-based cognitive psychotherapy aims at teaching patients to disengage from cognitive processes that are proposed to increase vulnerability to depression, by improving awareness and acceptance of negative thoughts and feelings. Several trials of this treatment method did not provide superior protection against recurrences of depression than control conditions ([@CIT0068]; [@CIT0013]; [@CIT0077]). However, one trial found it to be about as effective as long-term treatment with an antidepressant ([@CIT0013]), and others found beneficial effects among patients with at least three previous depressive episodes ([@CIT0110]; [@CIT0075]). Widely clinically employed cognitive-behavioral therapy was associated with significantly lower long-term recurrence rates of depression than with a control condition involving treatment as usual or nonspecific clinical management, again, but the benefits appeared to be limited largely to patients with three or more previous episodes ([@CIT0026]; [@CIT0010], [@CIT0012]). There is also some evidence that use of CBT during an index episode of acute depression may have long-lasting beneficial effects in limiting risks of relapse or recurrences for up to 2 years after initial remission ([@CIT0048]; [@CIT0023]).

In the present findings, notably, some trials found that psychosocial methods outperformed or significantly added to benefits of pharmacotherapies (e.g. [@CIT0026]; [@CIT0023]; [@CIT0068]; [Table 3](#T3){ref-type="table"}). Such findings encourage additional, well-designed, larger trials to test for long-term benefits of psychosocial methods, including their potential additional benefits when combined with antidepressants.

Finally, studies of effects of long-term ECT remain scarce. Two were identified that examined patients who had responded to ECT in an acute episode of major depression. Participants were then randomized to continue ECT with or without antidepressant medication, compared to other treatments that included an antidepressant plus lithium. Their findings favored ECT added or compared with medicinal treatments ([@CIT0033]; [@CIT0058]). A small "mirror-image" study found that maintenance ECT was associated with fewer and shorter psychiatric hospitalizations over 8 years compared to similar periods of illness before use of maintenance ECT ([@CIT0045]).

Effect of Multiple Depressive Recurrences {#s18}
-----------------------------------------

Several of the studies reviewed found that treatment effects appeared to be superior among patients with multiple (especially ≥3) previous episodes of depression ([@CIT0080]; [@CIT0110]; [@CIT0072]; [@CIT0075]; [@CIT0053]). This relationship was more likely with psychotherapy ([@CIT0110]; [@CIT0075]; [@CIT0010], [@CIT0012]) than with pharmacotherapies ([@CIT0080]; [@CIT0026]; [@CIT0072]; [@CIT0064]; [@CIT0065]; [@CIT0064]; [@CIT0068]; [@CIT0013]; [@CIT0053]; [@CIT0077]; [@CIT0113]). Mechanisms involved are not clear, but more recurrent depressive disorders may be particularly responsive to efforts to apply psychological methods to modify demoralization and adverse patterns of thinking and behavior proposed to contribute to a risk of depression ([@CIT0010]). An alternative possibility is that multiple previous recurrences may select for cases with particularly high future risks of recurrence, and so provide a statistical advantage in controlled trials.

Effect of Duration of Initial and Later Treatment {#s19}
-------------------------------------------------

In meta-regression analyses, the only factors that appeared to be associated with greater drug-placebo differences were a longer initial treatment of index episodes of acute depression and a longer duration of long-term treatment that followed. Presumably, longer initial treatment places antidepressant-treated patients at an advantage in terms of adequate recovery from an acute depressive episode, with greater stabilization and resistance to relapses within several initial months, and longer treatment is disadvantageous for placebos. We also found recently that shorter duration of initial treatment with an antidepressant, especially less than 4--6 months, is followed by higher relapse risks with a placebo ([@CIT0005]). The possibility that such effects influenced the outcome of continuation trials could not be tested since data on the duration of initial placebo treatment in index depressive episodes were not available.

Limitations {#s20}
-----------

This review has several noteworthy limitations. First, there were relatively few well-designed studies involving non-pharmacological treatments, and very few involving specific combinations of treatment methods that are commonly employed clinically on an empirical basis. Second, follow-up periods ranged from several months to five years (average: up to 2 years), with a probable excess of new episodes within the early months, although the actual times to new episodes usually were not reported. That is, not all trials are likely to represent fair testing of protection against recurrences (not contaminated by relapses) of major depression, which probably requires several years given the natural history of the illness, in which episodes typically reoccur less than yearly ([@CIT0003]). Third, many studies involve "enriched" designs, in which patients were required to respond favorably to short-term treatment of an initial episode of acute major depression. Such case selection is likely to limit potential generalization of findings to broader clinical populations. Fourth, many intermediate- or long-term trials involve discontinuation of an active treatment in patients barely recovering from an acute episode of depression. Such treatment discontinuation itself may contribute to inferior outcomes in the placebo arms of trials, especially if treatment discontinuation is abrupt or rapid ([@CIT0004], [@CIT0005]; [@CIT0003]). Fifth, we did not include studies of juvenile depression or study mainly geriatric depression. However, recent reviews of maintenance trials in these groups indicate that the evidence available is encouraging, but much less abundant than in adult MDD ([@CIT0065]; [@CIT0020]; [@CIT0121]). Additional limitations include the need to re-use single placebo arms in some trials that compared more than one active treatment; however, we carried out sensitivity analyses based on including only one treatment/control comparison from each of such studies, and found very minor effects on the meta-analytically pooled outcomes (not shown). In addition, there is a general lack of relevant clinical details concerning previous depressive episodes in many studies, and little consideration of subjective wellness and improved functioning as clinically relevant components of outcomes, and we found very little evidence that specific clinical or biological characteristics were considered that might contribute to predicting the likelihood of accepting, tolerating, and benefitting from particular long-term treatments.

Conclusions {#s21}
===========

Most of the pharmacotherapy trials reviewed showed significantly lower rates of relapse or recurrence of depressive episodes among adult patients diagnosed with MDD compared to placebos. These treatments involved the use of SNRIs, SSRIs, and other agents with demonstrated short-term efficacy in acute major depressive episodes ([@CIT0115]; [@CIT0003]). ECT also had some benefit in recurrence prevention, but remains inadequately tested in the long term. Fewer long-term, monotherapy trials of psychotherapies have been reported; most involve cognitive-behavioral techniques, sometimes with antidepressants continued. Nevertheless, most psychotherapy trials have found some evidence of long-term benefit, especially in patients with three or more previous episodes of major depression. Despite the evidence of efficacy of antidepressants, and suggestive support for some forms of psychosocial interventions compared to placebos or other controls, the present findings underscore the substantial rates of long-term unresolved morbidity in treated MDD patients ([@CIT0031]); with treatment, relapse rates averaged 23.3% (in 8.4 months), and recurrences averaged 24.6% to 36.8% (in 24--27 months; Tables S1--3). That conclusion strongly encourages further efforts to develop more effective and better-accepted treatments and evaluations of the effects of dosing and of specific combination therapies, conducted over periods longer than a year, and efforts to design trials so as to limit biases associated with case selection and artifacts associated with treatment discontinuation, especially soon after initial apparent clinical recovery, as well as to examine predictors of positive or unfavorable outcomes and of nonadherence to long-term treatments.
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